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Exercise medicine for advanced prostate cancer
Nicolas H. Hart, Daniel A. Galvão, and Robert U. Newton

Purpose of review
Exercise is a provocative medicine, known for its preventive, complimentary and rehabilitative role in the
management of cancer. Impressively, exercise is also emerging as a synergistic and targeted medicine to
enhance symptom control, modulate tumour biology and delay disease progression, with the potential to
increase overall survival. Given the complex clinical presentation of advanced prostate cancer patients and
their omnipresent comorbidities, this review describes the current and potential role of exercise medicine in
advanced prostate cancer.
Recent findings
Exercise has been shown to be safe, feasible and effective for advanced prostate cancer patients, inclusive of
patients with bone metastases; a previously excluded population due to patient and clinician fear of adverse
events. Preclinical data provide insight into the ability of exercise to modulate cancer-specific outcomes, may
synergistically increase the potency of chemotherapy and radiotherapy and may endogenously and/or
mechanically suppress tumour formation, growth and invasion in visceral and skeletal tissue. Epidemiological
studies have also shown an association between physical activity and increased survival.
Summary
Exercise oncology is rapidly evolving, with impressive possibilities that may directly improve patient
outcomes in advanced prostate cancer. Research must focus on translating preclinical trials into human
clinical trials and investigate the direct effect of exercise on overall survival.
Keywords
adjuvant, autoregulation, synergistic, targeted, tumour biology

INTRODUCTION
Prostate cancer represents the second most common
cancer in men worldwide, and is predicted to
substantially rise in developed nations owing to
sustained population growth, increased life expectancies and an ageing population [1,2]. Fortunately,
the advent and widespread adoption of serological
prostate-specific antigen (PSA) screening programmes has notably improved the early detection,
diagnosis, treatment and management of prostate
cancer, demonstrably improving survival outcomes.
Impressively, this has led to an increase in 5-year
survival rates from 68 to 99.7% in recent decades,
with a 10 and 15-year survival rate of 99 and
94%, respectively, when detected early [3,4]. As
such, prostate cancer survivorship is an emerging
and critically important field of study, focused on
the effective management of new, recurrent and
persistent symptoms across the disease spectrum
to explicitly enhance patient health, wellbeing
and quality of life [5,6]. Unfortunately, most studies
exploring survivorship focus their attention on the
initial years of posttreatment survival, with limited
attention given to patient needs later in the disease
trajectory [6,7 ] when recurrence, castrate resistance
&

and/or metastatic proliferation inevitably result in
progression to advanced prostate cancer, whereby
patient needs magnify [7 ].
Advanced prostate cancer is characterized by the
recurrence and/or invasion of the primary carcinoma to secondary sites (i.e. nodal, visceral or
skeletal metastases) and/or the development of
resistance to first-line hormone therapy (androgen
deprivation therapy; ADT) whereby androgen independent progression occurs (castrate-resistant prostate cancer; CRPC) [8]. Men with advanced prostate
cancer present a significant challenge to clinicians,
&
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KEY POINTS
 Exercise is a safe and effective medicine for advanced
prostate cancer, including for patients with bone
metastases; a historically excluded patient population
with a high disease burden and magnified clinical
needs. Advanced prostate cancer patients should
therefore participate in exercise programmes, under
clinical supervision.
 Exercise may act synergistically to improve the potency,
delivery, effectiveness and tolerance of chemotherapy
and radiotherapy in advanced prostate cancer patients.
This has been presented in preclinical orthotopic
models to date. Future studies should aim to translate
findings to patient-focused human clinical trials.
 Exercise may endogenously and mechanically suppress
tumour formation, growth and invasion in visceral and
skeletal tissue by modulating cancer-specific outcomes.
This has been demonstrated in preclinical orthotopic
models to date. Future studies should aim to translate
findings to patient-focused human clinical trials.
 Physical activity has been associated with lower risk of
cancer-specific and all-cause mortality. However,
exercise will likely yield even greater survival benefits,
and this is being investigated by the INTERVAL-MCRPC
clinical trial, using metastatic castrate-resistant prostate
cancer patients, launched in 2016.
 Exercise programmes designed for advanced prostate
cancer patients should always be supervised,
individualized, periodized, progressive and
autoregulated. Autoregulation is a particularly
important for this patient population, given their disease
profile, age, omnipresent comorbidities and associated
treatment toxicities over time.

because of their high disease burden and omnipresent comorbidities, in addition to common treatment-related side-effects stemming from secondline hormone therapies (abiraterone and enzalutamide) [9], first-line and second-line chemotherapies
(docetaxel and cabazitaxel) [10], radionuclear therapies (strontium-89, samarium-153 and radium-223)
[11] and emergent immunotherapies [12], the
optimal sequencing of which has yet to be determined. Indeed, the vast majority of advanced prostate cancer patients (>80%) will develop bone
metastases, which is a currently incurable stage of
disease leading to palliation, poor prognoses and
numerous clinical complications [13,14 ]. It is therefore a high priority and of significant clinical interest to devise and implement strategies to safely and
effectively reduce the disease burden and treatment
toxicity profile of advanced prostate cancer patients;
particularly, strategies which are inexpensive, noninvasive and able to be widely implemented.
&
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Exercise is an emerging and provocative therapy
in oncology, inherently aligned with the ‘exercise
medicine’ movement [15–17], which shows excellent promise to meet this patient need.

EXERCISE MEDICINE
Exercise was first considered a potential therapy for
cancer patients and survivors in the mid-1980s [18–
20], with only a further 25 exercise oncology studies reported in the subsequent two decades [21].
Increasingly, over the last decade, exercise medicine
has rapidly ascended as a key field of interest in the
prevention [22] and management [23] of cancer,
while emerging as a potential therapeutic agent to
delay disease progression [24 –26 ,27,28 ,29] and
increase overall survival [29,30,31 ,32 ,33,34].
Primarily, researchers have focused their attention
on the use of exercise in the neoadjuvant and adjuvant settings as a preventive, preparatory and rehabilitative tool for surgery (presurgical and
postsurgical programmes) [35,36], and for symptom
control during and/or following primary treatments, including radiotherapy, chemotherapy and
hormone therapy (particularly ADT) postdiagnosis
[37–40]. Collectively, this body of research has produced level 1 evidence [23], asserting the role of
exercise for cancer patients to improve quality of life
across several key metrics, including the mitigation
of cancer-related fatigue [41 ] and restoration of
physical function and exercise capacity [22,42],
notably in response to treatment driven changes
in body composition [23]. The effectiveness of exercise as a neoadjuvant and adjuvant therapy to minimize, manage and, in some cases, reverse the sideeffects of primary therapies has been promising to
date [42–46].
Exercise oncology (i.e. the application of exercise medicine in cancer) has also continued to
broaden, with several novel avenues being explored
through preclinical orthotopic models that have the
potential to significantly improve outcomes in
advanced prostate cancer patients once translated
to human clinical trials [47,48,49 ,50 ,51–54].
Indeed, the impressive ability of exercise to potentially modulate cancer-specific outcomes is of direct
clinical interest and warrants rigorous scientific
inquiry. Beyond neoadjuvant and adjuvant applications, exercise is emerging as a synergistic medicine (i.e. increasing the potency or effectiveness of
concomitantly applied therapies) and targeted
medicine (i.e. exerting its own systemic and localized anticancer effects, independent of other therapies) to underpin delays in disease progression and
improvements in survival for advanced cancer
patients. For example, synergies between exercise
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and
chemotherapy
have
been
identified
[49 ,50 ,51], with aerobic exercise demonstrating
an ability to interfere with tumour-driven dysregulation of angiogenesis; acting to restore and normalize tumour vasculature, thus improving blood
supply and tumoral perfusion as mechanisms to
enhance chemotherapeutic efficacy [49 ,50 ,
51–55]. This same angiogenic response may also
synergistically improve the effectiveness of radiotherapy [51–55], as reversible DNA damage can be
stabilized if sufficient oxygen is present (i.e. oxygen
enhancing effect of radiotherapy) [55], which could
be optimized through exercise driven provasculature changes, resulting in increased tumour cell
death. This is yet another avenue of exploration
for future research. When extrapolated, this may
also lead to synergistic improvements in the
potency of other systemically delivered therapies
&&
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inclusive of emerging immunotherapies in the prostate cancer treatment mix, or endogenous immune
agents produced by various organs in the body that
are driven by exercise [15].
Provocative evidence also exists to promote the
potential independent role of exercise medicine for
advanced prostate cancer patients. Putatively, exercise is thought to alter tumour biology by numerous
mechanisms in response to a variety of modes and
dosages (Fig. 1) [24 ]; however, the direct influence
of exercise on tumour biology remains largely
unknown, despite many hypothesized mechanical
and nonmechanical mechanisms of action
[47,48,49 ,50 ,51–59,60 ]. Specifically, exercise
regulates endocrine–paracrine activity, immune
system function, blood glucose and cholesterol
levels, insulin responses and body composition
and may epigenetically modulate tumour cell
&&
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FIGURE 1. Potential mechanisms by which exercise might modulate tumour biology and delay disease progression. Thus far,
the exact mechanisms of this effect have yet to be established; although, some evidence exists for a contribution from a variety
of diverse mechanisms. Reprinted with permission [24 ].
&&
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proliferation, telomere length, telomere enzyme
activity, tumour vascularity, oxidative stress
capacity, platelet cloaking and platelet adhesion
[61–66]. This emerging field of exercise medicine
(i.e. biological alterations driven from biomechanical stimuli) [67] in exercise oncology presents practitioners with unique opportunities to target
tumour formation, growth and invasion of primary
or secondary prostate carcinomas through exercise
interventions. For example, aerobic exercise has
been shown to stimulate natural killer cell production, mobilization and infiltration in to
tumours, producing an approximate 60% reduction
in tumour incidence and growth across several
different preclinical tumour models [68 ]. Similarly, controlled mechanical compressions of
skeletal sites with known bone metastases have been
shown to interfere with tumour-driven dysregulation of osteogenesis, producing an approximate
80% reduction in tumour growth rate in osteolytic
models, while preserving skeletal integrity by
approximately 70% in loaded versus unloaded conditions [47]. Cautiously, these preclinical findings
use animal models over disparate time-periods, and
require confirmatory human trials, some of which
are currently in progress [69 ], though provide
promising insights into exercise medicine independent of other therapies.
Epidemiological studies support the role of
physical activity (i.e. incidental and/or nonspecific
activities requiring bodily movement) and its association with delayed disease progression and increased
overall
survival
[27,28 ,29,30,31 ,32 ,33,34].
Specifically, prediagnosis physical activity has been
linked to tumour vessel normalization, which
reduces the propensity of tumours to metastasize
(i.e. delay disease progression) and has the potential
to produce a 6.6–17.1-fold risk reduction in prostate
cancer mortality [70 ,71]; whereby postdiagnosis
moderate-to-vigorous physical activity has been
linked to reductions in all-cause and prostate cancer-specific mortality of between 30 and 60% (pooled
risk reduction ¼ 0.62, 95% confidence interval: 0.47–
0.82) [31 ,32 ,33,34,72 ], depending on the type,
duration and frequency of physical activity reported.
However, these studies provide associations using
patient self-reported measures only and do not demonstrate a dose–response or load–adaptation insight
into cause and effect between physical activity, disease progression or overall survival. Consequently,
studies are yet to explore the role of exercise (i.e.
purposeful, prescriptive, programmed and progressive activities of a specific nature; the nomenclature of
which is often incorrectly used synonymously with
physical activity) on disease-specific endpoints and
such interventions would most certainly produce
&&

&

&

&&

&&

&&

&&

250

&&

&

www.supportiveandpalliativecare.com

even greater benefits than those analysing selfreported physical activity. To address this need, a
Global Action Plan (GAP4) has been funded by the
Movember Foundation, with a multinational Phase
III exercise trial (INTERVAL-MCRPC: https://clinicaltrials.gov/ct2/show/NCT02730338) launched, and
currently underway to directly examine the effects
of exercise medicine on disease progression and overall survival in metastatic castrate-resistant prostate
cancer patients [73 ].
&

TREATMENTS, TOXICITIES AND EXERCISE
Exercise and antiandrogen therapies
Endocrine modification therapies are common firstline treatments for prostate cancer (beyond radical
prostatectomy and radiation therapy), aiming to suppress testosterone released from the testes and/or to
block androgen receptor uptake of testosterone by
cancer cells, producing an environment commensurate with castration [74,75]. ADT remains the primary
hormonal therapy for local and metastatic prostate
cancer patients, proving an extremely successful
pharmacological avenue to slow the progression of
certain prostate cancers. On the contrary, long-term
exposure to ADT inevitably leads to resistance, thus
becoming ineffective due to tumour adaptability,
desensitization to drug action and systemic acclimatization to the castrate environment [74–77]. This
generates a rapid rise in PSA levels and velocity,
indicating an advancement of the disease to CRPC.
Consequently, extragonadal androgen sources start
to sustain tumour growth despite castrate levels of
testosterone, requiring second-line therapies to be
introduced into the treatment mix [76,77].
Novel pharmacological agents which inhibit
androgen receptors have recently been developed
as second-line hormonal therapies to countenance
extragonadal sources of androgen, including derivations from blood and bone marrow, successfully
extending overall survival by 4–5 months [78,79]
in castrate-resistant patients. Specifically, Abiraterone Acetate (Zytiga; Janssen, Beerse, Belgium) and
Enzalutamide (Xandti; Astellas, Illinois, USA) are
prominent antiandrogen drugs in the standard of
care landscape when treating CRPC patients, which
act as selective inhibitors to obstruct androgen
uptake and utilization by prostate carcinomas
regardless of production site (gonadal or extragonadal), thus considered to be very effective at suppressing testosterone in the testes, adrenal glands and the
tumour itself, reducing testosterone levels by a further 90% beyond castrate levels [74–80]. Although
androgen-deprivation therapies are proving effective in slowing prostate cancer progression, with
Volume 11  Number 3  September 2017
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FIGURE 2. Skeletal muscle depletion (sarcopenia-related disorders) induced by androgen deprivation therapy, expected to be
greater in severity for castrate-resistant prostate cancer patients treated with antiandrogen therapies generating maximal
androgen suppression. Adapted with permission [82 ].
&

improvements to survival; observational and longitudinal evidence highlight the burden of treatment
to patients, which may be exacerbated by novel
antiandrogen therapies [81,82 ] (Fig. 2), yet could
potentially be managed through exercise.
ADT induces rapid loss of muscle and bone mass,
increased central adiposity and body fat, and is
therefore a precursor for the onset of metabolic
diseases and other comorbidities such as type II
diabetes and/or cardiovascular disease; culminating
&

in physical and functional decline, increased
fatigue, heightened fragility, decreased psychosocial
health and a reduced quality of life [37–40,41 ,
42–46,82 ,83–86]. Given that novel antiandrogen
therapies induce an even greater blockade of androgen beyond castration levels (i.e. maximal androgen
suppression), these reported side-effects are likely to
be more pronounced (Fig. 3), presenting even
greater clinical concerns for advanced prostate cancer patients. Although exercise is demonstrably
&

&

FIGURE 3. Theoretical model illustrating musculoskeletal fitness reduction during normal aging, androgen deprivation therapy
and maximal androgen suppression, highlighting the potential role of exercise to increase musculoskeletal fitness and improve
physical reserve capacity. Adapted with permission [46].
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beneficial for patients receiving ADT to prevent,
preserve or reverse treatment-related side-effects
[45,46], this has yet to be demonstrated in patients
receiving maximal antiandrogen suppression.
Indeed, exercise is very likely to mitigate fatigue
commonly reported by patients on novel antiandrogen therapies [41 ,81], and may synergistically assist
in the mitigation of resistance to enzalutamide, with
natural killer cells recently implicated in the suppression of androgen receptor splicing variant 7
(ARv7) (i.e. an androgen receptor splicing variant
linked to the development of resistance) [87 ]. As
natural killer cell production and mobilization
increases following exercise [68 ], by extension,
this may aid in the suppression of ARv7; however,
further research is required.
&

&&

&&

Exercise and chemotherapy
Chemotherapies provided to patients with
advanced prostate cancer aim to provide symptom
control, delay disease progression and increase survival; however, often present with their own clinical
challenges and side-effects. Docetaxel remains the
mainstay of first-line taxanes, with cabazitaxel
established as a second-line taxane in eligible
patients (i.e. consideration of bone marrow reserves,
bone marrow quality, hepatic function and patient
presentation) in favour of mitoxantrone; with cabazitaxel also available as a first-line taxane for
patients resistant to docetaxel [10,74]. Owing to
the side-effects of cytotoxic therapies, coupled with

Neutrophil Count
(Log ANC in Cycle 1, x 109/L)

100.0

side-effects of other therapies (i.e. ADT in hormonesensitive patients), patients may not tolerate full
dosages across all cycles of treatment, and in some
cases may be ineligible for further chemotherapy
treatments if bone marrow and organ function is
compromised [88–90]. Further, patients commonly
present with high levels of fatigue, physical impairment and develop neutropenia following chemotherapy [91–94] which may lead to patients electing
to refuse further chemotherapy dosages or undergo
additional courses. Strategies to alleviate treatment
toxicities and maintain hepatic and physical function are thus required.
Exercise is well established as a therapy to mitigate cancer-related fatigue [22,41 ], restore physical
function and enhance physical fitness [23,42,44,95];
however, exercise may have broader clinical benefits
for prostate cancer patients receiving chemotherapy.
For example, neoadjuvant exercise may improve
patient preparation and physical tolerance of firstline chemotherapy, inclusive of posttherapy recovery, with body composition established as a predictor
of chemotherapeutic toxicity [96 ]. Furthermore,
adjuvant exercise may synergistically increase cytotoxic circulation and intratumoural delivery of chemotherapy, thus increasing therapeutic potency
[49 ,50 ], and may mitigate, restore or reverse side-effects associated with chemotherapy, inclusive of
reductions in neutropenia onset, duration and
severity of nadir (Fig. 4) following proposed improvements in immune function [97–99]. Neoadjuvant
and adjuvant exercise therefore has the potential
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FIGURE 4. Theoretical model illustrating the potential acute and aggregate neutrophil response to exercise (dashed line)
versus usual care (solid line) during chemotherapy cycles, highlighting a potentially reduced severity and duration of nadir
(i.e. region of lowest neutrophils during neutropenia, where infection risk is at its highest).
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to assist patients to receive their full individual and
aggregate doses of chemotherapy, and coupled with
posttherapy exercise, may promote bone marrow
quality [97] and improve patient physical condition
to heighten clinical eligibility to receive and tolerate
second-line chemotherapy; two clinically meaningful outcomes for advanced prostate cancer patients
that are worthy of exploration.

EXERCISE PROGRAMMING
Clinical considerations
Owing to their variable treatment histories, lifestylerelated and disease-related comorbidities and agerelated decline, advanced prostate cancer patients
will present with complex clinical cases that will
influence the modality, volume, frequency,
duration and intensity of exercise prescribed, and
the manner in which their exercise programme
progresses. Commonly amongst them is bone metastases, a historical barrier to exercise observed in
over 80% of advanced cancer patients [100,101].
For patients with bone metastases, it is currently
recommended to use exercises that avoid directly
loading skeletal regions where metastatic lesions
exist (Table 1) [102]. Current studies exploring the
safety, feasibility and preliminary efficacy of targeted loading of skeletal sites with bone metastases
are currently underway [69 ], with results soon to
be released.
&

Autoregulation, periodization and exercise
selection
Advanced prostate cancer patients may present with
numerous treatment side-effects of varying magnitudes at a given exercise session, or across multiple
exercise sessions. To accommodate for transient
changes and fluctuations in a patient’s wellbeing

through-out courses of treatment and through-out
their disease progression, all exercise programmes
should be individualized (i.e. based on a needs
analysis and physical assessment) and progressive
using autoregulation (i.e. a method in which cancer
patients progress at their own pace based on daily
and weekly variations in their health, performance
capability, recovery capacity or scheduling commitments) [103,104]. Autoregulation is an important
concept, allowing patients to consultatively selfdetermine their capabilities at each session collaboratively with the supervising clinical exercise
physiologist, thereby lowering intensity or volume
if the patient is fatigued or unwell, or raising intensity or volume if the patient is energetic and motivated. Commensurate with other standard exercise
principles, exercise programmes should be periodized (i.e. the systematic planning and phasic organization of exercise volume and intensity, including
deloading periods to promote patient recovery),
commence conservatively, and include a variety
of exercise types and modalities.
Advanced cancer patients should receive medical
clearances from either their oncologist (i.e. cancerspecific medications and clearances), cardiologist
(i.e. cardiac-specific medication and clearances) and/
or general practitioner (i.e. other medications and
comorbidity clearances) prior to engaging in an
exercise programme, which may limit the modality
of exercise permitted. Nevertheless, exercise programmes should ideally involve a multimodal
approach with aerobic and resistance exercise of varying intensities and volumes to target the cardiorespiratory and musculoskeletal systems, respectively (Table
2), and to promote various biochemical, hormonal
(endocrine–paracrine) and immune responses to disparate modalities. Current clinical exercise guidelines
[105–107] recommend achieving a combination of
150 min of moderate, or 75 min of vigorous aerobic
exercise coupled with 2–3 resistance exercise sessions

Table 1. Modular multimodal exercise programme for patients with bone metastases
Resistance
Metastases site

Aerobic

Trunk

Lower

H

H

H

H

H

H

H

H

H

Pelvis

H

Lumbar spine

H

Thoracic spine/ribs

H

Proximal femur

H

All regions

H

H
H

WB

Flexibility

Upper

H

NWB

Static

H

H

H

H

H

H

H, target exercise region; , exclusion of shoulder flexion/extension/abduction/adduction – inclusion of elbow flexion/extension; , exclusion of hip extension/
flexion – inclusion of knee extension/flexion; , exclusion of spine/flexion/extension/rotation; NWB, nonweight bearing (e.g. cycling); WB, weight bearing
(e.g. walking). Reproduced from [102].
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Table 2. Exercise programming across modalities: definitions and recommendations
Exercise modality

Description and recommendation

Aerobic exercise

Exercise that provides stress to the cardiorespiratory system (heart, blood vessels and lungs), and targets
cardiometabolic health. This can be performed at moderate-to-high intensities, under continuous or intermittent/
interval conditions (MICT/HIIT)
Examples: cycle ergometers, treadmills, cross-trainer ergometers

MICT (moderate
intensity continuous
training)

Constant moderate intensity work at a level that can be maintained for an extended period of time without fatigue.
Patients may require MICT sessions to be split into discrete bouts at the earlier stages of their programme, until
fitness and endurance develops
Intensity: RPE 5–6, (60–70% HRmax); RPE 4 during deload
Work durations: 20–40 min
Rest durations: 0–2 min
Number of sets: 1–2 sets

HIIT (high-intensity
interval training)

Short bouts of high-intensity work, separated by periods of active or passive recovery. Patients may have a transient
increased in risk of fall for 10 min following the completion of a HIIT session. Monitoring patient response during
and following work bouts is required
Intensity: RPE 8–9, (80–90% HRmax); RPE 7 during deload
Work durations: 30–60 s
Rest durations: 90–120 s
Number of sets: 4–6 sets

Resistance exercise

Exercise that is performed against resistance (bodyweight or external load) and aims to stress the musculoskeletal
system (muscle-bone), with muscle a key secretory and endocrine organ. Dynamic, compound, whole-body
movements should be performed first, prior to isolated single-joint activities. Trunk flexion and extension exercises can
be incorporated into the cool-down portion of the programme, along with flexibility exercises for the exercised muscle
Examples: weight machines, free weights (dumbbells and barbells), body-weight exercises, weighted objects (gym
sticks and power bags)
Intensity: 6–12 RM
Number of sets: 2–4 sets
Number of Exercises: 6–8 involving large muscle groups

Impact exercise

Exercise that involves impact, putatively thought to target the skeletal system and bone health. Patients with bone
metastases are currently contraindicated for impact exercise, as safety has yet to be demonstrated in these
patients. Patients with no known bone metastases can perform impact exercises as tolerated. Start conservatively,
from a foundation of 12–36 resistance exercise sessions, and build into programme for volume and difficulty
Examples: marching, two-legged jumps, hopping, skipping, bounding
Repetitions: 10–15 repetitions
Number of sets: 2–3 sets
Number of exercises: 2–4 exercises involving upper and lower body

HIIT, high-intensity interval training; HRmax, heart rate maximum; MICT, moderate-intensity continuous training; RM, repetition maximum; RPE, rating of perceived
exertion using the BORG10 scale.

for cancer patients and survivors. However, owing to
heightened clinical concerns and patient fear of
skeletal and other adverse events [69 ], only 30%
of advanced prostate cancer patients with bone metastases reported meeting aerobic exercise guidelines;
with the remaining 70% either insufficiently or
completely inactive (i.e. performing no aerobic exercise at all) [14 ]. Given the historical safety concerns
surrounding resistance exercise in this population
(with safety and feasibility recently demonstrated
[100,101]), resistance exercise participation would
be even lower than those reported for aerobic exercise.
Although any activity is better than no activity, it is
incumbent upon clinicians to promote patient
&

&
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engagement with exercise physiologists and treat exercise as a medicine for advanced prostate cancer, one
which all patients should participate.

CONCLUSION
Exercise medicine is rapidly evolving as an emerging
and provocative therapy in oncology, with excellent
promise to meet the broad and magnified needs of
advanced prostate cancer patients. This review highlights established clinical evidence, developing preclinical evidence and potential future avenues of
novel research pertaining to the role of exercise as
an adjuvant, synergistic and targeted therapy. In
Volume 11  Number 3  September 2017
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particular, we highlight the powerful potential of
exercise to enhance chemotherapeutic and radiotherapeutic effectiveness, interfere with tumourdriven dysregulation of angiogenesis and osteogenesis and delay disease progression and extend survival. Importantly, due to the complex clinical
presentations of advanced prostate cancer patients,
this review provides exercise prescription and programming recommendations to ensure that exercise
participation is flexible and effective, yet safe and
well tolerated by patients. Lastly, we assert the need
for future research to focus on translating impressive
preclinical outcomes, to patient-focused human
clinical trials, to continue to establish exercise as
an essential therapy for inclusion into standard of
care practices in oncology.
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